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Introduction
Candida species are important causative agents of healthcare-associated infections, especially in critically ill patients with intravascular catheters, those on broadspectrum antibiotics, those on mechanical ventilation, and those on immunosuppressive agents and parenteral nutrition. 1 Candida albicans remains the predominant cause of invasive candidiasis and accounts for more than 50% of all cases; however, the incidence of invasive candidiasis due to non-albicans Candida species such as C. tropicalis, C. glabrata, and C. parapsilosis is increasing. 2, 3 Candida dubliniensis was first characterized by Sullivan et al in 1995. 4 Since then, however, very few cases of candidiasis due to this rare pathogen have been reported. C. dubliniensis shares many features with C albicans and, therefore, can be misidentified in routine laboratory methods in clinical microbiology laboratory. Thus, the incidence of infection due to this causative pathogen may be underreported. In Taiwan, C. dubliniensis has only been reported in association with oropharyngeal carriage in HIVinfected patients. 5 In this report, we describe two cancer patients with catheter-related fungemia due to C. dubliniensis in Taiwan.
Case reports Case 1
A 62-year-old woman with rheumatic heart disease status after mitral valve replacement and thyroid papillary carcinoma was admitted to the National Taiwan University Hospital because of congestive heart failure and progressive dyspnea. She was intubated for acute respiratory failure and was placed on dialysis. Several episodes of healthcare-associated infections developed during hospitalization for which she received piperacillinetazobactam, ertapenem, and cefepime. One month later, a new onset of fever occurred, and ceftazidime was prescribed after collecting blood for culture. Five days later, blood cultures (Becton Dickinson Microbiology Systems, Sparks, MD, USA) from the central venous catheter (CVC) yielded C. dubliniensis. The CVC was removed, and intravenous amphotericin B (50 mg/day) for 14 days was added to the regimen to cover candidemia. Thereafter, there was no fever and repeated blood culture did not yield Candida spp.
Case 2
A 71-year-old man had received three courses of gemicitabin and cisplatin as treatment for bladder cancer. Two months after the final treatment, the patient presented with symptoms and signs of progressive bladder cancer. A radical cystectomy was performed. Approximately 8 days after the operation, the patient developed fever. Empirical therapy with ceftazidime was initiated but the patient responded to the therapy unsatisfactorily. Culture of peripheral blood and blood from the CVC yielded C. dubliniensis. The CVC was removed, and intravenous fluconazole (400 mg/day) was administered for 14 days. His clinical condition gradually improved, and the patient was discharged uneventfully after completing the full course of antibiotics.
The two isolates of C. dubliniensis were identified to the species level by conventional laboratory procedures and the Vitek Yeast Biochemical Card identification system (bioMérieux Vitek, Marcy l'Etoile, France) (bionumber 6102544061305370, 99% probability). An oligonucleotide array system targeting the internal transcribed spacer 1 and 2 region of the rRNA genes and sequence analysis of the amplified internal transcribed spacer region using the BLAST program confirmed that the isolates were indeed C. dubliniensis (GenBank accession no. HQ457430.1, 99% identity). 6 The MIC values of nine antifungal agents against the two C. dubliniensis isolates were determined by a commercial system with the broth microdilution method (Sensititre YeastOne, SYO; Trek Diagnostic Systems, West Sussex, UK). The two isolates were susceptible to fluconazole, voriconazole, itraconazole, caspofungin, micafungin, anidulafungin, and 5-flucytosine (Table 1) . 7 
Discussion
C. dubliniensis can cause invasive infections, especially in immunocompromised patients. This rare pathogen has been reported to cause human infection in the United States, Australia, Europe, and Argentina. The prevalence of C. dubliniensis as the causative agent of candidiemia ranges from 0.96% in Argentina to approximately 2% in the United States and the United Kingdom.
8e12 To the best of our knowledge, these are the first two cases of fungemia due to C. dubliniensis in Taiwan. Both cases occurred in the same 2500-bed medical center during the period 2009e2010.
In this study, both cases were classified as healthcareassociated catheter-related bloodstream infections, and one of the patients had cancer during the episode of infection. In a study reported by Chen et al, 13 the majority of patients (19 of 22, 86%) with C. dubliniensis fungemia had healthcare-associated infections, and 79% of them had vascular access devices.
The clinical outcomes of patients with C. dubliniensis fungemia have not been well defined because of the limited number of cases. In one series of four patients with C. dubliniensis fungemia, one patient died as a consequence of this infection. 11 In another study, the 30-day crude mortality rate was 27.7% (5/18). 13 In the present study, both patients survived for 5 and 8 days, respectively, without any antifungal therapy and had favorable responses after antifungal treatment and removal of the catheters. These findings might indicate the potential low virulence of the organism. However, further large-scale studies are needed to better understand the clinical manifestations and prognosis of C. dubliniensis fungemia.
We tested the in vitro activity of nine antifungal agents against the two C. dubliniensis isolates. The MICs of the tested echinocandins were highest for capsofungin, and the MICs of the tested azoles were in the order voriconazole < itraconzaole < posaconazole < fluconazole. The MIC values were in agreement with those reported previously 13 against 22 C. dubliniensis isolates. In that study, the MIC 90 values of the tested azoles were in the order voriconazole (0.016 mg/mL) < itraconzaole Z posaconazole (0.125 mg/mL) < fluconazole (1.0 mg/mL). Based on the above-mentioned in vitro studies, azoles remain the drugs of choice to treat C. dubliniensis infections.
In conclusion, C. dubliniensis is an emerging pathogen that causes invasive infections, and it may play an important role in the clinical setting of bloodstream infections.
14 Healthcare-associated catheter-related bloodstream infections due to this pathogen may respond well to appropriate antifungal agent and catheter removal. The in vitro studies showed there was no resistance to antifungal agents but that azoles are effective against C. dubliniensis.
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